Published in Ann Surg Oncol on November 08, 2007
Metastatic amelanotic melanoma with occult primary masquerading as sarcoma. J Clin Diagn Res (2015) 0.75
Management of regional lymph node basins in melanoma. Ochsner J (2010) 0.75
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med (2004) 6.87
Multidisciplinary approach to deep-seated lesions requiring radiologically-guided fine-needle aspiration. Diagn Cytopathol (1998) 2.04
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87
Fine needle aspiration in the diagnosis of metastatic melanoma. J Am Acad Dermatol (2000) 1.56
Technology assessment in anatomic pathology. An illustration of test evaluation using fine-needle aspiration biopsy. Arch Pathol Lab Med (1994) 1.44
Workup bias in prediction research. Med Decis Making (1987) 1.34
Fine needle aspiration biopsy in the diagnosis of lymphadenopathy in 1,103 patients. Role, limitations and analysis of diagnostic pitfalls. Acta Cytol (1995) 1.30
Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol (1998) 1.05
Fine needle aspirate smear morphology in metastatic melanoma. Acta Cytol (1989) 0.92
Fine needle aspiration cytology and immunocytochemistry of metastatic melanoma. Cytopathology (1991) 0.90
The relationships among performance measures in the selection of diagnostic tests. Arch Pathol Lab Med (1997) 0.87
The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol (1997) 0.86
Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. Am J Clin Pathol (2007) 0.85
Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases. Cancer (2000) 0.84
Interpretation of fine needle aspiration cytology of the breast: a comparison of cytological, frozen section, and final histological diagnoses. Cytopathology (2004) 0.84
Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. J Natl Cancer Inst (1986) 0.84
Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer (2000) 0.82
Influence of training and experience in fine-needle aspiration biopsy of breast. Receiver operating characteristics curve analysis. Arch Pathol Lab Med (1987) 0.81
Fine-needle-aspiration cytodiagnosis of recurrent malignant melanoma. J Surg Oncol (1980) 0.78
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 6.06
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med (2015) 4.64
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51
Direct RNA sequencing. Nature (2009) 4.37
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Cutaneous melanoma. Lancet (2005) 3.94
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Quantification of the yeast transcriptome by single-molecule sequencing. Nat Biotechnol (2009) 3.86
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Recalibrating Equus evolution using the genome sequence of an early Middle Pleistocene horse. Nature (2013) 3.45
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol (2004) 2.99
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
Virtual terminator nucleotides for next-generation DNA sequencing. Nat Methods (2009) 2.83
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol (2008) 2.69
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol (2007) 2.62
Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med (2011) 2.60
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA (2004) 2.58
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med (2003) 2.41
Keystone flap reconstruction of primary melanoma excision defects of the leg-the end of the skin graft? Ann Surg Oncol (2008) 2.36
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res (2009) 2.26
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum (2006) 2.17
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol (2012) 2.13
Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol (2010) 2.06
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improving doctors' letters. Med J Aust (2002) 1.98
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
True single-molecule DNA sequencing of a pleistocene horse bone. Genome Res (2011) 1.88
The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol (2008) 1.87
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol (2012) 1.79
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum Genomics (2004) 1.71
Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2005) 1.71
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer (2003) 1.68
Absence of distinguishing senescence traits in human melanocytic nevi. J Invest Dermatol (2012) 1.65
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol (2005) 1.63
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol (2012) 1.63
Diagnosis and management of sebaceous carcinoma: an Australian experience. ANZ J Surg (2008) 1.62
Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol (2011) 1.62
Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst (2014) 1.61
Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma. Lancet Oncol (2007) 1.61